This article is more than 5 years old. Information may no longer be current.
VIDEO: New lessons in ACS provide insight on treatment approaches, troponin assays
CHICAGO — Jennifer Ann Tremmel, MD, an interventional cardiologist at Stanford University Medical Center, reviews findings from highlighted original research that stand to enhance patient care in the setting of ACS from initial assessment to therapy selection.
After noting movement in the field around antithrombotic agents, PCSK9 inhibitors and complete revascularization at the time of STEMI, she goes on to discusses the promise of risk factor profiling and genetics in personalizing medicine and the impact of door-to-balloon time vs. symptom-to-balloon time on mortality.
Tremmel reviews associations between shifting circadian rhythms during natural disasters and MI occurrence time in the context of Hurricane Katrina, then touches on findings on death, MI, stroke and bleeding risk with ticagrelor (Brilinta, AstraZeneca) vs. clopidogrel from the SWEETHEART registry.
Finally, she covers questions raised by an investigation into high-sensitivity troponin levels regarding gender- and age-specific populations. “High sensitivity troponin may be giving us more information than we actually want, but at the same time it may be giving us information about patients that we would otherwise miss.”